Dr. Dimou on Managing Disease Progression in NSCLC
Anastasios (Tassos) Dimou, MD, shares advice from managing patients with non–small cell lung cancer who experience disease progression following therapy.
Dr. Dimou on Emerging Treatment Options in BRAF+ Lung Cancer
Anastasios (Tassos) Dimou, MD, discusses emerging treatment options in BRAF-positive lung cancer.
Dr. Dimou on Progress Made in ALK+ Lung Cancer Treatment
Anastasios (Tassos) Dimou, MD, discusses the progress made in the treatment of patients with ALK-positive lung cancer.
Dr. Dimou on Limitations of TMB as a Biomarker in Lung Cancer
Anastasios (Tassos) Dimou, MD, discusses the limitations of tumor mutational burden as a biomarker in lung cancer.
Immunotherapy Must Become More Precise and Personalized in Lung Cancer
Selecting the Appropriate CAR T-Cell Therapy for Patients with R/R LBCL
Is There a Potential Role for Rapcabtagene Autoleucel in R/R LBCL?
PD-1 Inhibitor Combinations, Alternative Therapeutic Approaches Are Moving the Needle in NSCLC
2 Clarke Drive Cranbury, NJ 08512